✦ LIBER ✦

Evidence-based use of recombinant FVIIa (NovoSeven®, NiaStase®) for the treatment of hemophilia with inhibitors in children and adolescents

✍ Scribed by Brahm Goldstein; Brian Geldziler; Jens Bjerre; Stephanie Seremetis

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Evidence for the Use of Recombinant Fact

✍ Janet Birchall; Simon J. Stanworth; Michael R. Duffy; Carolyn J. Doree; Christop 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 212 KB

Consensus protocol for the use of recomb

✍ P. L. F. GIANGRANDE; J. T. WILDE; B. MADAN; C. A. LUDLAM; E. G. D. TUDDENHAM; N. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

Recombinant factor VIIa analog (vatrepta

✍ ERICH V. DE PAULA; KAAN KAVAKLI; JOHNNY MAHLANGU; YASMIN AYOB; STEVEN R. LENTZ; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 231 KB

PIH3 RISK OF WEIGHT GAIN WITH THE USE OF

✍ D Bhowmik; H Chen; RR Aparasu; V Bhatara 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

Use of the Breakthrough Series Collabora

✍ Lori Ebert; Lisa Amaya-Jackson; Jan M. Markiewicz; Cassandra Kisiel; John A. Fai 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 343 KB

The Evidence for the Use of Recombinant

✍ Man-Chiu Poon 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 345 KB